Eventide Asset Management LLC Cuts Holdings in Celcuity, Inc. $CELC

Eventide Asset Management LLC decreased its stake in shares of Celcuity, Inc. (NASDAQ:CELC) by 80.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 313,679 shares of the company’s stock after selling 1,275,120 shares during the quarter. Eventide Asset Management LLC’s holdings in Celcuity were worth $31,287,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Ogorek Anthony Joseph NY ADV boosted its position in shares of Celcuity by 19.7% during the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after acquiring an additional 109 shares in the last quarter. US Bancorp DE boosted its position in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of Celcuity by 1.4% during the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after acquiring an additional 183 shares in the last quarter. Aristides Capital LLC boosted its position in shares of Celcuity by 2.0% during the 4th quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after acquiring an additional 303 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after acquiring an additional 319 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Down 1.1%

Shares of NASDAQ CELC opened at $88.55 on Friday. The stock has a market cap of $4.32 billion, a PE ratio of -22.71 and a beta of 0.10. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. Celcuity, Inc. has a 52-week low of $11.27 and a 52-week high of $151.02. The business has a 50-day moving average price of $119.81 and a 200 day moving average price of $111.22.

Celcuity (NASDAQ:CELC) last announced its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. Equities research analysts forecast that Celcuity, Inc. will post -3.69 earnings per share for the current year.

Wall Street Analyst Weigh In

CELC has been the subject of several analyst reports. Leerink Partners set a $155.00 price objective on Celcuity in a research report on Tuesday, June 2nd. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research report on Thursday, May 28th. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a research report on Wednesday, June 3rd. Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Finally, HC Wainwright lowered their price objective on Celcuity from $185.00 to $145.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Celcuity currently has an average rating of “Moderate Buy” and a consensus price target of $152.09.

Insider Transactions at Celcuity

In related news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at $949,509.60. This represents a 57.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the sale, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 37,000 shares of company stock valued at $5,111,950. Insiders own 13.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.